Part 2: What can businesses do if globalisation unravels?

Business leaders face significant risks if the world becomes more fragmented. But there is much they can do now to avoid it and create instead a new, more sustainable globalised business environment.

Part 1: The end of globalisation?

Business leaders face significant risks if the world becomes more fragmented.

Going Global: Are graduates prepared for a global workforce?

In a recent EIU study, 63% of graduates say they were rewarded by employers for their international experiences during higher education. Furthermore, two thirds say that international experience has provided them with an edge in their careers. But why is it that only 34% of students with access to international experience actually take advantage of it? Learn more by watching the above video. 

 

Going Global: Are graduates prepared for a global workforce?

75% of graduates who had any form of international experience while at university believe they became more culturally aware as a result. Why is this important? Now more than ever, employers value the kinds of non-technical skills that are learned through study abroad and other internationally focused programs. In fact, graduates who have international experience have found more success finding a job after six months than those without it. So why aren't more students taking advantage of international opportunities during higher education?

The changing biopharma risk equation

Pharmaceutical companies are in an expansive mode. With rapid advances being made in the development of new therapies, including stem-cell derived therapies and gene therapies, and a growing cohort of potential customers in the burgeoning middle classes of emerging markets, expansion into both new product categories and geographic regions is a priority for most companies.

The changing biopharma risk equation

Pharmaceutical companies are in an expansive mode. With rapid advances being made in the development of new therapies, including stem-cell derived therapies and gene therapies, and a growing cohort of potential customers in the burgeoning middle classes of emerging markets, expansion into both new product categories and geographic regions is a priority for most companies.

The changing biopharma risk equation

However, this class of product—ranging from well-established large-molecule drugs to truly novel therapies—poses major challenges because of their scientific complexity and sophisticated development requirements. Furthermore, expanding the drug pipeline isn’t the only growth strategy most companies are pursuing: They are also planning to expand geographically and expect to face various risks doing so, including unfamiliar regulatory environments, shifts in pricing and customers’ ability to pay.

Simon Baptist on shipping and globalisation

Simon Baptist on shipping and globalisation

The ICT Globalisation Index

Read Report in  | 

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week